Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | HLX02 + HLX22 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| HLX02 | HLX-02|HLX 02 | HER2 (ERBB2) Antibody 79 | HLX02 is a biosimilar to Herceptin (trastuzumab), which potentially reduces growth of ERBB2 (HER2)-expressing tumors (PMID: 38982548). | |
| HLX22 | HLX-22|HLX 22 | HER2 (ERBB2) Antibody 79 | HLX22 is a monoclonal antibody targeting an epitope in ERBB2 (HER2) subdomain IV, which potentially decreases ERBB2 (HER2) signaling and viability of ERBB2 (HER2)-expressing tumor cells, and reduces tumor growth (PMID: 38982548). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|